Medical Condition

myelofibrosis

Total Trials

10

Recruiting Now

10

Trial Phases

Phase 2, Phase 1, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for myelofibrosis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — myelofibrosis Clinical Trials

How many clinical trials are currently recruiting for myelofibrosis?

ClinicalMetric currently tracks 10 actively recruiting clinical trials for myelofibrosis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 10. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for myelofibrosis?

myelofibrosis research spans Phase 1 (3 trials), Phase 2 (4 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a myelofibrosis clinical trial?

Eligibility criteria for myelofibrosis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Masonic Cancer Center, University of Minnesota 1 trial

University of Michigan Rogel Cancer Center 1 trial

Sumitomo Pharma America, Inc. 1 trial

University Hospital, Angers 1 trial

Aspera Biomedicines, Inc. 1 trial

Recruiting Clinical Trials

NCT05805605 Phase 2

Recruiting

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center, Univers...

View Trial →

NCT01973881

Recruiting

Quantitative MRI for Myelofibrosis

University of Michigan Rogel C...

View Trial →

NCT04176198 Phase 1, Phase 2

Recruiting

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Enrollment

240 pts

Location

United States, Austr...

Sponsor

Sumitomo Pharma America, Inc.

View Trial →

NCT05710211

Recruiting

Clonal Architecture of ASXL1-mutated Myelofibrosis

University Hospital, Angers

View Trial →

NCT07250646 Phase 1

Recruiting

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

Aspera Biomedicines, Inc.

View Trial →

NCT07623161 Phase 3

Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

Enrollment

324 pts

Location

United States, Argen...

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Enrollment

58 pts

Location

United States, Belgi...

Sponsor

Karyopharm Therapeutics Inc

View Trial →

NCT05025488 Phase 1

Recruiting

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Haplo-HSCT for Myelofibrosis

Peking University People's Hos...

View Trial →

NCT06059391 Phase 2

Recruiting

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

City of Hope Medical Center

View Trial →

Related Conditions

myeloproliferative neoplasm (2) acute myelogenous leukemia (1) acute lymphocytic leukemia (1) biphenotypic acute leukemia (1) undifferentiated leukemia (1) prolymphocytic leukemia (1) chronic myelogenous leukemia (1) plasma cell leukemia (1) myelodysplastic syndromes (1) leukemia myeloid (1) myelodysplastic syndrome with excess blasts 1 (1) burkitt lymphoma (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology